Physician profile
Anna E Knackstedt
NPI 1821424219
$1,754.40
in general payments reported to CMS, 2019-2025
24 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $235 · 2023: $281 · 2024: $328 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $301.31 | 2025 | Cvac Aspiration System |
| 180 Medical, INC. | $248.40 | 2021-2025 | |
| Astellas Pharma US INC | $209.59 | 2021-2024 | Myrbetriq |
| Progenics Pharmaceuticals, INC. | $149.26 | 2022-2023 | Pylarify |
| Medtronic, INC. | $95.32 | 2021-2025 | Interstim |
| Myovant Sciences INC. | $83.62 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.46 | 2021-2023 | |
| Urogen Pharma, INC. | $74.33 | 2022-2025 | Jelmyto |
| Pfizer INC. | $61.42 | 2021-2025 | |
| Axonics, INC. | $54.76 | 2021 | |
| Janssen Biotech, INC. | $38.81 | 2021-2024 | Erleada |
| Endo USA, INC. | $38.05 | 2024-2025 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $35.41 | 2023-2024 | Orgovyx |
| Janssen Scientific Affairs, LLC | $34.48 | 2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $33.63 | 2024 | Provenge |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $33.48 | 2021 | |
| Boston Scientific Corporation | $32.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.63 | 2024 | |
| Hollister Incorporated | $25.63 | 2022 | |
| Endo Pharmaceuticals INC. | $24.74 | 2024 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $20.68 | 2025 | Adstiladrin |
| Olympus America INC. | $20.64 | 2025 | Itind System |
| Procept Biorobotics Corporation | $17.70 | 2024 | Aquabeam System |
| Abbvie INC. | $14.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Knackstedt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.